The immunogenicity and safety of the new, Indonesian DTwP-HB-Hib vaccine compared to the DTwP/HB vaccine given with the Hib vaccine

The UK Hib vaccine experience.

Haemophilus influenzae type b (Hib) is an important pathogen in children <5 years of age. The Hib conjugate vaccines were the first polysaccharide-protein conjugate vaccines to be used in routine childhood schedules. Their introduction in the UK in 1992 has resulted in the near elimination of Hib disease. The UK Hib vaccine programme has a number of unique features including an accelerated sche...

The immunogenicity, safety, and consistency of an Indonesia combined DTP-HB-Hib vaccine in expanded program on immunization schedule

BACKGROUND WHO recommended incorporation of Haemophilus influenzae type b (Hib) vaccination into immunization program. Indonesia would adopt Hib as a National Immunization Program in 2013. We aimed at analyzing immunogenicity, safety, and consistency of a new combined DTP-HB-Hib (diphtheria-tetanus-pertussis-Hepatitis B-Haemophilus influenza B) vaccine. METHODS A prospective, randomized, doub...

Stakeholder Perceptions of a (DTwP-HepB-Hib) Pentavalent Vaccine in the Uniject Injection System

Safety review results of Pneumococcal conjugate vaccine and Haemophilus influenzae type b(Hib) vaccine for pediatrics

Seven fatal cases have been reported in infants who simultaneously received multiple vaccinations including pediatric pneumococcal conjugate vaccine and Hib vaccine since March 2 2011.The joint meeting evaluated those cases based on the detailed information which was newly obtained from autopsy reports, medical records etc. on their courses and severities of the illnesses of these cases, includ...

Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine.

On August 19, 2009, the Food and Drug Administration (FDA) licensed Hiberix (GlaxoSmithKline Biologicals, Rixensart, Belgium), a Haemophilus influenzae type b (Hib) conjugate vaccine composed of H. influenzae type b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]) conjugated to inactivated tetanus toxoid (PRP-T). Hiberix is licensed for use as the booster (final) dose of the Hib va...